Filtered By:
Source: Current Medical Research and Opinion
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 147 results found since Jan 2013.
Stroke Risk Reduction Outweighed Bleeding Risk Increase from Vitamin K Antagonists Treatment among Nonvalvular Atrial Fibrillation Patients with High Stroke risk and Low Bleeding Risk.
CONCLUSION: In NVAF patients at high risk for stroke and low risk for bleeding, our data confirm the effectiveness of anticoagulation for stroke prevention. The decrease in stroke risk of anticoagulation may outweigh the risk of major bleeding events, particularly among elderly patients. Potential risks of warfarin during initiation warrant attention, especially among patients who stop and start therapy repeatedly.
PMID: 28008771 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 25, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease
Conclusion: Having stroke, MI, or PAD was associated with increases in HCRU and costs in patients with T2DM. Although PAD was associated with smaller per patient increases in total healthcare costs than patients with T2DM + stroke/MI, the higher frequency of incident PAD may make it more costly than MI or stroke in a large population of patients with T2DM.PMID:36134459 | DOI:10.1080/03007995.2022.2125259
Source: Current Medical Research and Opinion - September 22, 2022 Category: Research Authors: Aaron King Jigar Rajpura Yuanjie Liang Yurek Paprocki Chioma Uzoigwe Source Type: research
A nomogram for predicting the in-hospital risk of recurrence among patients with minor non-cardiac stroke
CONCLUSION: A prognostic nomogram that integrates clinical and imaging information to predict the in-hospital risk of stroke recurrence among patients after acute minor stroke was constructed and validated externally. The nomogram demonstrated adequate calibration and discrimination in both the development and validation cohort.PMID:35119325 | DOI:10.1080/03007995.2022.2038488
Source: Current Medical Research and Opinion - February 4, 2022 Category: Research Authors: Kaili Zhang Yalan Fang Haimei Fan Jing Ren Chang Liu Tingting Liu Yongle Wang Yanan Li Juan Li Jingwen Meng Lixia Qian Xinyi Li Xuemei Wu Xiaoyuan Niu Source Type: research
Real-World Evidence of Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in the United States: the REVISIT-US Study.
CONCLUSIONS: Rivaroxaban and apixaban were associated with less ICH than warfarin and both are likely associated with reductions in the combined endpoint. Further investigation to validate the numerically higher rate of ischemic stroke with apixaban versus warfarin is required.
PMID: 27633045 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 19, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
CONCLUSIONS: Ischemic stroke rates were significantly lower in the overall NVAF population for rivaroxaban vs warfarin users, including patients with eCrCl below 50 mL/min. For all renal function groups, major bleeding risks were not statistically different between treatment groups.
PMID: 28590785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 8, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population.
CONCLUSIONS: Among the DOACs in the study, only apixaban is associated with a significantly lower risk of stroke/SE and major bleeding and lower related medical costs compared to warfarin.
PMID: 28635338 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly diagnosed type 2 diabetes and early glycemic control.
CONCLUSIONS: Early and sustained HbA1c control between 6.5 and <7.0% is an important modifiable factor that helps reduce CV risk in patients with newly-diagnosed T2DM in real-world clinical practice.
PMID: 29065729 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 29, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
A retrospective study to assess resource utilization and costs in patients with post-stroke spasticity in the United Kingdom.
CONCLUSION: Costs after stroke for patients developing PSS are twice as high compared to patients who do not develop it, with the major driver being the number of hospital admissions. This highlights the need for better recording and closer management of PSS.
PMID: 29490512 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 3, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
CONCLUSION: QD NOACs prevented a significant number of strokes and caused no significant increase in MBs compared to BID NOACs which leads to significant net cost savings for NVAF patients in the US.
PMID: 30265159 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 29, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research
